Ophthalmology CRO on a Mission: Another Successful Year for Trial Runners!

Trial Runners has big plans for the future as an expanding company in the field of ophthalmology. As an ophthalmology CRO, the company is always looking for new ways to influence the industry with thought leading processes and strategy. The vision of the company includes expanding services and setting goals to continue providing services for the ophthalmic community.

Trial Runners holds a quarterly meeting to solidify long term goals and communicate company news. This year’s meeting at the first quarter has shown significant news for the expanding company. The company is venturing out into the operational space of rare disease and orphan drugs, a field that has subsidiary indications in ophthalmology (ie Alport Syndrome and Friedreich’s Ataxia). Trial Runners has experience in those indications, and they look forward to working in the expansive field of orphan drugs and rare disease.

As a company that values doing good in the field of pharmaceuticals, orphan drugs and rare disease is a natural fit for a next step in terms of service.

Some interesting facts about the field of rare disease:

  • There are approximately 7,000 different types of rare diseases and disorders, with more being discovered each day
  • 30 million people in the United States are living with rare diseases. This equates to 1 in 10 Americans or 10% of the U.S. population
  • Similar to the United States, Europe has approximately 30 million people living with rare diseases. It is estimated that 350 million people worldwide suffer from rare diseases
  • If all of the people with rare diseases lived in one country,  it would be the world’s 3rd most populous country
  • In the United States, a condition is considered “rare” it affects fewer than 200,000 persons combined in a particular rare disease group. International definitions on rare diseases vary. For example in the UK, a disease is considered rare if it affects fewer than 50,000 citizens per disease
  • 80% of rare diseases are genetic in origin, and thus are present throughout a person’s life, even if symptoms do not immediately appear
  • Approximately 50% of the people affected by rare diseases are children
  • 30% of children with rare disease will not live to see their 5th birthday
  • Rare diseases are responsible for 35% of deaths in the first year of life
  • The prevalence distribution of rare diseases is skewed – 80% of all rare disease patients are affected by approximately 350 rare diseases
  • During the first 25 years of the Orphan Drug Act (passed in 1983), only 326 new drugs were approved by the FDA and brought to market for all rare disease patients combined
  • According to the National Institutes of Health Office of Rare Disease Research, approximately 6% of the inquiries made to the Genetic and Rare Disease Information Center (GARD) are in reference to an undiagnosed disease
  • Approximately 50% of rare diseases do not have a disease specific foundation supporting or researching their rare disease


The people that need help for cures in the field of rare disease are in good hands with the ongoing efforts of clinical research around the globe.

Onward and upward is the only direction we know at Trial Runners! See you on the trail for cures!